doi:10.1016/0360-3016(95)93129-USDOSInternational Journal of Radiation Oncology*Biology*PhysicsWilliamJ.MackillopandHenryFuandCarolF.QuirtandPeterDixonandMichaelBrundageandY.YunzhengZhou
NeonMind operates two divisions: (i) a pharmaceutical division engaged in drug development of psychedelic compounds with two lead psilocybin-based drug candidates targeting obesity; and (ii) a medical services division focused on launching specialty mental health cl...